DOCSLIB.ORG

1 ALAN BERNSTEIN, OC, Phd, FRSC, LL.D. (Hon) CURRICULUM VITAE Executive Director

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ALAN BERNSTEIN, O.C., PhD, FRSC, LL.D. (Hon) CURRICULUM VITAE Executive Director: Global HIV Vaccine Enterprise 200 Park Avenue South, Suite 1501 New York, NY 10003 Tel: (212) 461-3692 / Fax: (212) 780-0607 E-mail: [email protected] Education and Training : 1968 B.Sc., (Honours), University of Toronto, Mathematics and Physics. 1972 Ph.D., University of Toronto, Medical Biophysics. Supervisor: Dr. James E. Till. 1972-1974 Postdoctoral Fellow, Imperial Cancer Research Fund Laboratories, London, UK. Appointments : 1974-1979 Assistant Professor, Dept. of Medical Biophysics, University of Toronto 1974-1985 Staff Member, Division of Biological Research, Ontario Cancer Institute, Toronto 1979-1984 Associate Professor, Dept. of Medical Biophysics, University of Toronto 1984- Professor, Dept. of Medical Biophysics, University of Toronto 1985-1994 Head, Division of Molecular and Developmental Biology, Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto 1986- Professor, Dept. of Medical Genetics and Microbiology, University of Toronto 1987- Member, Graduate Faculty, Institute of Medical Science, University of Toronto 1988-1994 Associate Director, Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto 1994-2000 Director, Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto 1995- Professor, Department of Medicine, Faculty of Medicine, University of Toronto 2000-2007 President, Canadian Institutes of Health Research, Ottawa 2008-2010 Honorary Research Fellow, School of Family & Public Health, Nelson Mandela Faculty of Medicine, University of Kwazulu-Natal, Durban, South Africa Honours Received : 1965-1967 Special Council of Innis College Scholarship 1968 The Innis College Award 1968 The James Loudon Gold Medal of the American Association for the Advancement of Science in Mathematics and Physics 1972-1973 The King George V Silver Jubilee Cancer Research Fellowship from the National Cancer Institute of Canada 1985-1991 McLaughlin Scientist 1986 Joseph J. Schiffer Exchange Visitor to Israel 1987 MRC Visiting Professor, Queen's University Kingston, February, 1987 1990 First Incumbent, Anne Tanenbaum Chair in Molecular and Developmental Biology, Samuel Lunenfeld Research Institute of Mount Sinai Hospital 1 1991 Fellow, Royal Society of Canada 1991-1996 International Research Scholar - Howard Hughes Medical Institute 1994-2000 The Koffler Chair for the Director, Samuel Lunenfeld Research Institute 1996 The 1996 Award of Merit, City of Toronto 1996 The McLaughlin Medal, The Royal Society of Canada 1997 The Robert L. Noble Award, National Cancer Institute of Canada 1998 The Genetics Society of Canada Award of Excellence 2000 The Canadian Society for Clinical Investigation/Royal College of Physicians and Surgeons of Canada 2000 Henry Friesen Award 2000 The Inaugural Distinguished Science Leadership Lecture, B.C. Cancer Agency & Vancouver General Hospital 2000 The Ottawa Life Sciences National Award of Merit 2001 The Australian Society for Medical Research Medal 2002 Award of Merit, Japan Society for the Promotion of Cancer Research 2002 Officer of the Order of Canada 2002 Queen Elizabeth II Jubilee Medal 2003 Guest of Honour, The Gairdner Foundation 2003 International Awards Dinner 2004 ‘Inspirational Innisian’, Innis College, University of Toronto 2004 Senior Fellow, Massey College, University of Toronto 2005 Member, The Canadian Academy of Health Sciences 2007 Doctor of Laws, honoris causa, Dalhousie University 2007 Médaille du mérite of the Institut de recherches cliniques de Montréal 2008 The Biotechnology Initiative Lifetime Achievement Award 2008 Health Charities Coalition of Canada Inaugural Award of Distinction 2008 Canadian Society of Biochemistry, Molecular and Cellular Biology Inaugural Arthur Wynne Gold Medal 2008 Canadian Association of University Research Administrators, Walter Hitschfield Award 2008 Gairdner Foundation Wightman Award 2009 Doctor of Science, honoris causa, University of British Columbia Key Lectures 1992 Second Allan J. Erslev Distinguished Lectureship, Jefferson Medical College, Thomas Jefferson University, Philadelphia 1995 Leukaemia Research Fund (of Great Britain) Speaker, Cancer Research Campaign 1995 Thomson Lecturer - Department of Biochemistry at McGill University, Montreal 2001 Garner King Lecturer, Research Day, University of Alberta 2001 The Telstra Address, National Press Club, Canberra, Australia 2002 The Inaugural Lecturer, The Alan Bernstein Distinguished Lecture Series, The McDonald Research Laboratories, University of British Columbia, Vancouver 2003 Keynote Address, Gairdner Foundation International Awards Gala, Toronto 2005 Inaugural Keynote Address, The Canadian Academy of Health Sciences, Vancouver Memberships in Scientific Societies : 2 1970- American Society for Microbiology 1977- Canadian Society for Cell Biology 1986- Genetics Society of Canada MEMBERSHIPS ON COMMITTEES FEDERAL BOARD MEMBERSHIPS : 2000-2007 Member, Canadian Health Services Research Foundation 2000-2007 Chair, Governing Council, Canadian Institutes of Health Research 2000-2007 Member, Board of Directors, Genome Canada 2000-2007 Health Canada Scientific Advisory Board 2000-2007 Steering Committee, Canada Research Chairs 2000-2007 Steering Committee, Networks of Centres of Excellence 2002-2004 Member, Board of Directors, Canada Foundation for Innovation 2002-2007 Associate Member, Natural Sciences & Engineering Research Council of Canada 2003-2007 Member, Prime Minister’s Advisory Committee on Science and Technology 2005-2007 Chair, Steering Committee, Canada Research Chairs BOARD MEMBERSHIPS (S ELECTION ): 1982 Member, Search Committee, Head, Division of Biological Research, Ontario Cancer Institute 1984 Member, Executive Committee, Division of Biological Research, Ontario Cancer Institute 1982-1984 Member, Research Advisory Group, National Cancer Institute of Canada 1984-1986 Member, Advisory Committee on Research, National Cancer Institute of Canada 1986-1988 Member, Task Force on Strategic Planning, National Cancer Institute of Canada 1986-1988 Chair, Advisory Committee on Research, National Cancer Institute of Canada 1987-1990 Member, Scientific Review Panel, Israel Cancer Research Fund 1988-1989 Member, MRC Working Group on Guidelines for Somatic Cell Gene Therapy for Disease 1988-1995 Member, Committee on Priorities & Planning, National Cancer Institute of Canada 1989-1995 Member, Scientific Board, Foundation Viamarconidieci, Italy 1989-1994 Member, International Scientific Council, Israel Cancer Research Fund 1989-1997 Member, Board of Directors, National Cancer Institute of Canada 1990 Member, Science Board, Biomedical Research Centre, Vancouver 1990 Member, Inter-Council Human Genome Advisory Committee 1990 Member-at-Large, National Cancer Institute of Canada 1991 Chair, Science Board, Biomedical Research Centre, Vancouver 1992-1995 Member, Medical Advisory Board, Thalassemia Research Foundation of Ontario 1992-1996 Member, Management & Executive Committees, Canadian Human Genome Project 1993 Member, Medical Research Council of Canada, Advisory Committee for Policy, Planning, Analysis and Evaluation 1993 Member, National Cancer Institute of Canada Task Force on International Affairs 1993 Member, Conjoint Review Committee, Faculty of Medicine, University of Western 3 Ontario 1993 Member, Molecular Medicine External Advisory Committee, Fred Hutchinson Cancer Research Center 1994-2000 Chair, International Scientific Council, Israel Cancer Research Fund, New York 1994-1997 Member, Standing Committee on Science and Research, Medical Research Council of Canada 1995-1998 Member, Scientific Advisory Board, Visible Genetics Inc., Toronto 1995-2000 Member, Board of Directors, Cancer Care Ontario, Toronto 1995-2000 Member, Research Advisory Committee, Cancer Care Ontario, Toronto 1996-2000 Member, Board of Scientific Counsellors, National Cancer Institute, National Institutes of Health, USA 1996-1999 Member, Mayor's Economic Partnerships Council, City of Toronto 1996- Member, The Committee of Excellence, Weizmann Institute of Science, Toronto 1997-2004 Member, Alberta Cancer Board - Advisory Committee on Research, Edmonton 1997-2000 Chairman, SAG, Biocatalyst Yorkton Inc., Toronto 1997-1999 Member, Seneca College - Biological Research Technology Advisory Committee, Toronto 1997-2000 Chair, Toronto Biotechnology Commercialization Centre Board 1998-1999 Member, Scientific Advisory Board, Fred Hutchinson Cancer Research Center, Seattle, Washington 1998-2000 Member, Roswell Park Cancer Institute's Scientific Advisory Board, Buffalo 1998- Member, Research Advisory Board, Juvenile Diabetes Foundation International, New York 1998-2000 Member, Ontario Science Centre Board of Trustees, Toronto 1998-1999 Member, Ontario Biotechnology Task Force, Ministry of Energy, Science & Technology, Toronto 1998-2000 Member, Unified Research Strategy Working Group, The Change Foundation, Toronto 1998-2000 Member, Board of Directors, The Gerry & Nancy Pencer Brain Trust, Toronto 1998 Member, Canadian Institutes of Health Research Task Force, Ottawa 1999-2000 Member, Scientific Advisory Board, Canji, Inc., San Diego 1999-2000 Member, Scientific Advisory Committee, Alberta Heritage Foundation for Medical Research, Edmonton, Alberta 1999-2003 Member, Scientific Advisory Board, The Van Andel Institute for Cancer Research, Grand Rapids, Michigan 1999-2000 Member, Advisory Board, Roswell Park Cancer Institute, Buffalo 1999-2000 Member, Board Development Committee, Cancer Care Ontario, Toronto
Recommended publications
  • Which Canadian Charities Had the Largest Assets in 2014?

    Which Canadian Charities Had the Largest Assets in 2014?

    www.canadiancharitylaw.ca Which Canadian charities had the largest assets in 2014? By Mark Blumberg (March 23, 2016) We recently reviewed the T3010 information for 2014. It covers about 84,370 of the 86,000 registered charities that have so far filed their return and that have been entered into the CRA’s database. Canadian registered charities are currently required to disclose on the T3010 their assets. The total assets of all the 84,370 registered charities were about $373,050,327,255.00. Below we have a table of Canadian charities and how much they spent as reported for the 2014 fiscal year. Thank you to Celeste Bonas, an intern at Blumbergs, for helping with this project. The Sean Blumberg Transparency Project is in memory of my youngest brother Sean Blumberg. Sean was a sweet, kind person, a great brother who helped me on a number of occasions with many tasks including the time consuming and arduous task of reviewing T3010 databases and making them into something useful. As part of the Sean Blumberg Transparency Project, Blumbergs has been releasing information on the Canadian charity sector to provide a better understanding of the size, scope, complexity and challenges of the sector. Please review my caveats at the end about the reliability and usage of T3010 information. 1 www.canadiancharitylaw.ca List of Canadian charities with the largest assets in 2014 Line 4200 Name of Canadian Registered Charity largest assets 1. ALBERTA HEALTH SERVICES $9,984,222,000.00 2. THE MASTERCARD FOUNDATION $9,579,790,532.00 3. THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO $7,681,040,000.00 4.
  • 2015 Annual Report

    2015 Annual Report

    1 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................. 2 HISTORY OF THE GAIRDNER FOUNDATION .................................................................................... 3 MISSION ...................................................................................................................................................... 3 NATIONAL AND STUDENT OUTREACH PROGRAMS ....................................................................... 4 MESSAGE FROM THE CHAIR ............................................................................................................... 5 MESSAGE FROM THE PRESIDENT/SCIENTIFIC DIRECTOR ......................................................... 6 2015 YEAR IN REVIEW ............................................................................................................................. 7 REPORT ON 2015 OBJECTIVES ............................................................................................................ 14 THE YEAR AHEAD: OBJECTIVES FOR 2016 ..................................................................................... 16 THE GAIRDNER FOUNDATION VALUES OUR 2015 SPONSORS ................................................... 18 GOVERNANCE ......................................................................................................................................... 20 MEDICAL REVIEW PANEL 2015 .........................................................................................................
  • 2015 Annual Summary Corporate Plan

    2015 Annual Summary Corporate Plan

    The Gairdner Foundation Corporate Plan 2015 1 TABLE OF CONTENTS PAGE Section I About the Gairdner Foundation 2 Objectives and Achievements to Date 5 Benefits 7 Section II Performance Results for 2014 Activities 7-8 Detailed 2014 Evaluations 9-10 Planned Activities and Anticipated Results 2015 11 Section III Financial Summary 12 Planned Receipts and Disbursements 2015 13-15 Section IV Risk Management 16 Section V Performance Monitoring 17-19 2 THE GAIRDNER FOUNDATION CORPORATE PLAN EXECUTIVE SUMMARY HISTORY The Gairdner Foundation was created by James A. Gairdner to recognize and reward the achievements of medical researchers whose work “contributes significantly to improving the quality of human life”. The Foundation is a Canadian organization that has never lost sight of its primary mission – the recognition of scientists it deemed to have made the most important breakthrough discoveries in biomedical science. It’s recipients are responsible for the discovery of the structure of DNA, the eradication of smallpox, CT scans, MRI machines, the human genome, the cure for ulcers, and the vaccine against HPV, to name a few. Since the first awards were granted in 1959, the Canada Gairdner Awards have become Canada's foremost international award- and one of the most prestigious awards in medical science. Our track record of consistent high quality adjudication and selection by the independent adjudication committees have resulted in global recognition and esteem. The Gairdner was incorporated in December 1957 as a charitable corporation under the laws of the Province of Ontario, Canada. During 2013, the Foundation was continued as a federal corporation under the Canada Not-For-Profit Corporations Act.
  • Canada Scientific Advisory Committee (CSAC)

    Canada Scientific Advisory Committee (CSAC)

    Canada Scientific Advisory Committee (CSAC) Alan Bernstein, PhD – Co-chairperson Canadian Institute for Advanced Research Toronto, Ontario Alan Bernstein is President of the Canadian Institute for Advanced Research (CIFAR), Canada’s global research institute. From 2008- 2011, Bernstein was the executive director of the Global HIV Vaccine Enterprise, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine. Previously, he served as the founding president of the Canadian Institutes of Health Research (2000-2007), Canada’s federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada. After receiving his PhD from the University of Toronto, and following postdoctoral work in London, Bernstein joined the Ontario Cancer Institute (1974-1985). In 1985, he joined the new Samuel Lunenfeld Research Institute in Toronto, was named Associate Director in 1988 and then Director of Research (1994-2000). Internationally known for his contributions to our understanding of the molecular basis of cancer, Bernstein has made extensive contributions to the study of stem cells, hematopoiesis and cancer. He chairs or is a member of advisory and review boards in Canada, the US, UK and Italy. Bernstein has received numerous awards and honourary degrees for his contributions to science, including the 2008 Gairdner Wightman Award, induction into the Canadian Medical Hall of Fame, and the Henry G. Friesen International Prize in Health Research. He is a Senior Research Fellow of Massey College, received the Order of Ontario in 2018 and was appointed an Officer of the Order of Canada in 2002.
  • ANNUAL REPORT 2015/2016 Message from the Minister of Research, Innovation and Science

    ANNUAL REPORT 2015/2016 Message from the Minister of Research, Innovation and Science

    ANNUAL REPORT 2015/2016 Message from the Minister of Research, Innovation and Science On behalf of the Government of Ontario I am pleased to have the opportunity to extend my thanks to the Ontario Institute for Cancer Research (OICR) for another successful year in its progress to meet the cancer challenge. A report issued recently by Cancer Care Ontario tells us that one in two Ontarians will develop cancer in their lifetime and cancer is the leading cause of death in the province. We have to do everything possible to alleviate the burden of cancer on Ontario families by improving the prevention, detection, diagnosis and treatment of cancer. We are proud of our investment in OICR over the last 10 years and recently approved the Institute’s Strategic Plan for 2016-2021. OICR has demonstrated leadership in the cancer community not only in its research programs but also in its focus on moving discoveries into the clinic. An example is the development of a novel oncolytic viral immunotherapy which is now in clinical trials. Through OICR’s commercialization partner, the Fight Against Cancer Innovation Trust, financial and in-kind support are attracted which makes it possible to accelerate development and therefore bring new hope to patients. The past year has been one of accomplishment and one of transition. Dr. Calvin Stiller, who was instrumental in the creation of the Institute, has stepped down as Chair of the Board of Directors. We are most grateful for his vision and leadership. Dr. Tom Hudson, who built the Institute, attracted talented researchers and launched provincial, national and international initiatives that are helping to make Ontario a world leader in cancer research, has moved on to the next phase of his career.
  • Princess Margaret Cancer Centre Annual Report

    Princess Margaret Cancer Centre Annual Report

    2 015 A NNU A L REPORT 3 Leadership Message 4 Our Program 4 Who we are Welcome to the 2015 Annual Report for the Princess Margaret Cancer Centre at the University Health Network (UHN). This year proved to be both exciting and engaging as we continue to deliver revolutionary cancer care for our patients, and we are looking 6 Clinical Care forward to sharing the progress we have made. The 2015 edition showcases the recent 6 Our Clinical Programs LEADERSHIP activities and accomplishments of our people, departments, disease groups, and research and education programs. As one of the largest comprehensive cancer treatment facilities in the world, we have a great deal to share as we continue our efforts to be on the 8 Personalized Cancer Medicine MESSAGE frontiers of medical, surgical and radiation oncology, embracing the latest technology 8 Our Strategy and international best-practices, and setting standards for patient care. 9 We Are Transforming Patient Care In 2015, we celebrated 20 years of our presence on University Avenue; the hub of the discovery district. The move not only signified our commitment to meet the increased 11 We Are Augmenting Correlative Cancer Biology demands and evolving needs of our patients, but also encouraged collaboration, innovation, and research, enabling us to continue making progress in conquering cancer. 12 We Are Accelerating Guided Therapeutics Today, we again embrace change as we drive implementation of our space plan, with Marnie Escaf MHA, HBBA 15 We Are Expanding Novel Therapeutics Senior Vice President a focus on redeveloping facilities to improve the patient experience, including patient Executive Lead amenities, access, flow, and wayfinding.
  • Dr. Adolfo J. De BOLD

    Dr. Adolfo J. De BOLD

    Dr. Adolfo J. de BOLD September 2015 Page 1 of 40 HOME ADDRESS: OFFICE ADDRESS: 5503 South Island Park Drive Department of Pathology and Laboratory Manotick, Ontario K4M 1J2 Medicine Phone: (613) 692-6194 University of Ottawa, Faculty of Medicine 4155-451 Smyth Road Ottawa, Ontario K1H 8M5 Phone: (613) 562-5422 [email protected] EDUCATION 1961 - 1967 National University of Córdoba, Argentina 1968 Professional Degree: Clinical Biochemist 1968 - 1973 School of Graduate Studies, Queens University, Kingston, Ontario, Canada 1971 M.Sc. (Experimental Pathology) "Studies on the Relationship between the Catecholamine Distribution in the Atrium and the Specific Granules Present in Atrial Muscle Cells" 1973 Ph.D. (Experimental Pathology) "The Relationship Between Morphology and Function in the Atrial Cardiocyte. A study With Emphasis on the Secretory Characteristics of the Mammalian Atrium" PROFESSIONAL APPOINTMENTS 1974 Laboratory Scientist, Pathology Laboratory, Hotel Dieu Hospital, Kingston, Ontario, Canada. 1974 Assistant Professor of Pathology, Department of Pathology, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada (Tenured, 1981). 1982 Associate Professor of Pathology, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada. 1985 Professor of Pathology, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada. 1986-1993 Director of Research, University of Ottawa Heart Institute Research Centre, Ottawa Civic Hospital. 1989-1995 Distinguished Research Professor, Heart and Stroke Foundation of Ontario. 1986-1995 Adjunct Professor of Pathology, Queen's University, Kingston, Ontario, Canada. 1986-2013 Professor of Pathology and Laboratory Medicine Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada 1986-2013 Cross-appointment, Department of Cellular and Molecular Medicine, Faculty of Dr. Adolfo J.
  • NCI Budget Fact Book for Fiscal Year 1996

    NCI Budget Fact Book for Fiscal Year 1996

    NCI FACT BOOK National Cancer Institute 1996 U.S. DEPARTMENT NATIONAL INSTITUTES OF HEALTH AND OF HEALTH HUMAN SERVICES The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892. TABLE OF CONTENTS Page Organization Director's Biography ........................................ 1 Former Directors of the NCI .................................. 2 National Cancer Advisory Board .............................. 3 Division Boards of Scientific Counselors ........................ 4 President's Cancer Panel .................................... 5 Executive Committee Members ............................... 5 Organization Charts: National Cancer Institute ................................... 6 Office of the Director ...................................... 7 Division of Basic Sciences .................................. 8 Division of Clinical Sciences ................................ 9 Division of Cancer Epidemiology and Genetics ................. 10 Division of Cancer Prevention and Control .................... 11 Division of Cancer Treatment, Diagnosis and Centers ............ 12 Division of
  • Ed 376 019 Title Institution Pub Date Note Available From

    Ed 376 019 Title Institution Pub Date Note Available From

    DOCUMENT RESUME ED 376 019 SE 053 531 TITLE Grants for Science Education, 1992-1993. INSTITUTION Howard Hughes Medical Inst., Chevy Chase, MD. Office of Grants and Special Programs. PUB DATE 93 NOTE 141p. AVAILABLE FROMHoward Hughes Medical Institute, Office of Grants and Special Programs, 4000 Jones Bridge Road, Chevy Chase, MD 20815-6789. PUB TYPE Guides Non-Classroom Use (055) EDRS PRICE MF01/PC06 Plus Postage. DESCRIPTORS *Biomedicine; *Grants; Higher Education; *Research; *Science Education; Secondary Education ABSTRACT To help strengthen education in medicine, biology, and related sciences, the Howard Hughes Medical Institute (HHMI) launched a grants program in these areas in 1987. The grants support graduate, undergraduate, precollege and public science education, and fundamental biomedical research abroad. This document provides summaries of all projects receiving grants in 1992 and is also, in effect, a 1992 annual report for each Programmatic Area supported by HHMI. (ZWH) *********************************************************************** * Reproductions supplied by EDRS are the best that can be made from the original document. *********************************************************************** 9- -.I I, .10 It vr .. * ie Ar -4",_ -7 \---(_,- 1 a Si It I 1 a a I tIt "PERMISSION TO REPRODUCETHIS U S DEPARTMENT OF EDUCATION GRANTED BY Orrice of Educahona, Research and irnomvernent MATERIAL HAS BEEN EDUCATIONAL RESOURCES INFORMATION CENTER (EPICI U ER-P,C This document has been reproduced as owed Iron the person or Organitation originating it C.1 Minor changes name been made to improve reproduction quality TO THE EDUCATIONALRESOURCES Ponis of vev, o ot),n(Ons staled .nlh'S doc 0 meal do not necessarily represent othc,a1 INFORMATION CENTER (ERIC) OE RI pc on or policy I I I a I -SET COPYAWAt'tMI 2 Copyright ©1993 by the Howard Hughes Medical Institute Office of Grants and Special Programs.
  • “Global Health Research”?

    “Global Health Research”?

    32 International Health: Feature Article Volume 3 No. 1, 2006 INTERNATIONAL HEALTH: FEATURE ARTICLE What is Canada Doing About “Global Health Research”? Vic Neufeld, MD, FRCPC ABSTRACT The worldwide investment in health research is currently about US$100 billion. Of this amount, less than 10% is targeted on the problems of societies that bear 90% of the global burden of illness. This article addresses this unac- ceptable situation in three ways: • by describing the global problem in more detail, including what is currently being done about it; • by summarizing Canada’s contribution to resolving the problem, both through federal government agencies, and through a new non-government organization: the Canadian Coalition for Global Health Research (CCGHR); • by suggesting what Canadian university students might consider doing about it. This includes getting informed, getting involved, and considering “global health” as one component of their future careers. The article concludes with the conviction that this is a remarkable moment for Canadians to play a more active role in global health—and indeed in global citizenship more broadly. WHAT IS CANADA DOING ABOUT “GLOBAL about the fact that research efforts to address this burden HEALTH RESEARCH”? appeared to be too small and ineffective. A major 2-year study was undertaken by the Independent International Commission n 2002, the worldwide investment in health research was on Health Research for Development (CHRD). The about US$100 billion. It is a startling fact that of this Commission released what has become a landmark report in Iamount, less than 10% was directed to research on problems 1990.1 Among its findings, the CHRD reported that about 93% of societies that bear 90% of the global burden of illness.
  • News Release

    News Release

    NEWS RELEASE: June 14, 2005 Health care leaders create Canada’s first national health advisory body The Canadian Academy of Health Sciences will give Government and the public comprehensive expertise and advice on health issues EDMONTON - When the President of the United States wants advice on a public health issue, he calls the United States’ National Academies. When the Prime Minister of Great Britain wants to seek similar counsel, he usually turns to the Royal Society of Britain. But when the Prime Minister of Canada wants similar advice, who does he call? Well, that’s not always entirely clear, given the more narrowly defined mandates of many Canadian organizations. Now, however, owing to a recent initiative by a group of leading health care leaders and researchers, the Prime Minister will be able to call the Canadian Academy of Health Sciences (CAHS), recently created to: • Develop informed, strategic assessments on urgent health issues; • Inform public policy on these issues; • Enhance Canada’s readiness to deal with global health issues; and, • Provide a recognized and authoritative Canadian health science voice internationally. According to one of the Academy’s key organizers, the establishment of the Academy is long over due—and all the more pressing given the potential global health threats to Canadians, most recently exemplified by the SARS threat. “Ask Canadians what they care about most, and they answer unequivocally: ‘health,’” explains University of Alberta Professor of Medicine Paul Armstrong, CAHS’s first president. “It makes sense, therefore, that Canada should have an organization that government—and Canadians—can turn to for sound, impartial advice and research on pressing health issues.” The organization will also have an international role to play, representing Canada’s interests abroad and working closely with other nations’ parallel agencies.
  • The Committee

    The Committee

    2016-2017 Annual Report Faculty of Medicine Honours and Awards Committee Table of Contents 2 3 Committee 4 Background and Analysis 5 Faculty Laureates Committee 3 The Faculty of Medicine’s Honours and Awards Committee was struck in July 2010 to advise the Dean and Faculty on matters related to Honours and Awards. It meets several times each year to discuss ongoing and upcoming awards opportunities and overall policies and is comprised of faculty members chosen for their expertise in mentorship and leadership. The Committee is meant to enhance the existing nomination process for faculty rather than replace it, and operates in conjunction with departmental committees and the University Prizes and Awards Committee (UPAC). In general, the Honours and Awards Committee does not veto nominations and faculty members are free to nominate at their own discretion. An exception occurs when there are restrictions included in the prize guidelines regarding the number of nominations allowed per institution or faculty. While it is not necessary to involve the Committee with every nomination, it is useful to make the Committee aware of nominations or even the intention to nominate within the Faculty, particularly with regards to high-profile awards, as our office can often provide guidance and support. A list of awards the Committee regularly works with can be found here. Exclusions It should be noted that, with some exceptions, the recognition opportunities considered by the Honours and Awards Committee exclude: Investigator awards or career awards tied to grant submissions Fellowships that provide emancipation from university responsibilities Education or leadership awards Self-nominations Awards for students or postdoctoral fellows The selection of endowed chairs Administrative/support staff-specific awards Committee Members, 2016–2017 Abraham Fuks, Chair Philip E.